STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13, J. Immunol, vol.161, pp.5027-5038, 1998. ,
The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of the Th2 immunity and allergic airway inflammation, J. Immunol, vol.180, pp.1199-1206, 2008. ,
The analysis of tryptase in serum of sarcoidosis patients, Inflammation, vol.32, pp.310-314, 2009. ,
Immunosuppression followed by immunomodulation, J. Neurol. Sci, vol.277, pp.50-54, 2009. ,
Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation, J. Neuroimmunol, vol.130, pp.10-21, 2002. ,
Treatment of multiple sclerosis: role of natalizumab, Neurol. Sci, vol.30, pp.155-158, 2009. ,
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Ann. Neurol, vol.49, pp.290-297, 2001. ,
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis, Mult. Scler, vol.15, pp.238-243, 2009. ,
Monocyte chemoattractant protein 1 (MCP-1): an overview, J. Interferon Cytokine Res, vol.29, pp.313-326, 2009. ,
Glatiramer acetate (Copaxone®) therapy for multiple sclerosis, Pharmacol. Ther, vol.98, pp.245-255, 2003. ,
Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a, Acta Neurol. Scand, vol.116, pp.164-168, 2007. ,
A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern, J. Immunol, vol.168, pp.6199-6207, 2002. ,
Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease, Inflamm. Bowel Dis, vol.14, pp.458-470, 2008. ,
Anaphylaxis: lessons from mouse models, J. Allergy Clin. Immunol, vol.120, pp.506-515, 2007. ,
DOI : 10.1016/j.jaci.2007.07.033
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigenpresenting cells-specificity and promiscuity, Proc. Natl. Acad. Sci. U. S. A, vol.91, pp.4872-4876, 1994. ,
Novel synthetic amino acid copolymers that inhibit autoantigen-specfic T cell responses and suppress experimental autoimmune encephalomyelitis, J. Clin. Investig, vol.109, pp.1635-1643, 2002. ,
DOI : 10.1172/jci0215402
URL : http://www.jci.org/articles/view/15402/files/pdf
Expression and crystallization of the complex HLADR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.828-839, 1998. ,
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1, Nature, vol.404, pp.407-411, 2000. ,
Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients, Clin. Exp. Rheumatol, vol.26, pp.317-323, 2008. ,
Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.749-760, 2004. ,
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS, Neurology, vol.60, pp.853-860, 2003. ,
Diagnosis and treatment of multiple sclerosis, Fortschr. Med, vol.145, p.95, 2003. ,
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, pp.1268-1276, 1995. ,
The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, vol.25, pp.677-686, 2004. ,
Mitoxantrone: benefits and risks in multiple sclerosis patients, Neurol. Sci, vol.30, pp.167-170, 2009. ,
Macrophage inflammatory protein-1, Int. J. Biochem. Cell Biol, vol.36, pp.1882-1886, 2004. ,
Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation, J. Neuroimmunol, vol.92, pp.113-121, 1998. ,
Initiation and maintenance of Th2 cell identity, Curr. Opin. Immunol, vol.20, pp.265-271, 2008. ,
A functional IL-13 receptor is expressed on polarized murine CD4 + Th17 cells and IL-13 signaling attenuates Th17 cytokine production, J. Immunol, vol.182, pp.5317-5321, 2009. ,
Monoclonal antibodies in multiple sclerosis, Med. Sci, vol.25, pp.1113-1115, 2009. ,
Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1, J. Autoimmun, vol.24, pp.119-124, 2005. ,
DOI : 10.1016/j.jaut.2005.01.004
Role of mast cells in allergy, Nippon Rinsho, vol.67, pp.2083-2087, 2009. ,
Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 ad IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis, Clin. Exp. Immunol, vol.143, pp.357-362, 2006. ,
Amelioration of proteolipid protein 139-151-induces encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.743-754, 2004. ,
DOI : 10.1073/pnas.0403832101
URL : http://www.pnas.org/content/101/32/11743.full.pdf
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur. J. Immunol, vol.1, pp.242-248, 1971. ,
DOI : 10.1002/eji.1830010406
The glatiramoid class of immunomodulator drugs, Expert Opin. Pharmacother, vol.10, pp.657-668, 2009. ,
DOI : 10.1517/14656560902802877
Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained, Neurology, vol.59, pp.1284-1286, 2002. ,
DOI : 10.1212/wnl.59.8.1284
Risk-benefit assessment of glatiramer acetate in multiple sclerosis, Drug Saf, vol.24, pp.979-990, 2001. ,
DOI : 10.2165/00002018-200124130-00005